Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 447,063
  • Shares Outstanding, K 363,466
  • Annual Sales, $ 31,080 K
  • Annual Income, $ -200,400 K
  • EBIT $ -67 M
  • EBITDA $ -64 M
  • 60-Month Beta 0.98
  • Price/Sales 6.14
  • Price/Cash Flow N/A
  • Price/Book 3.57

Options Overview Details

View History
  • Implied Volatility 421.18% (+247.64%)
  • Historical Volatility 113.05%
  • IV Percentile 98%
  • IV Rank 70.74%
  • IV High 558.03% on 02/24/25
  • IV Low 90.38% on 01/20/26
  • Expected Move (DTE 11) 0.2975 (24.79%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 120
  • Volume Avg (30-Day) 1,621
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 36,342
  • Open Int (30-Day) 32,468
  • Expected Range 0.9025 to 1.4975

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.08
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +9.09%
on 01/30/26
1.8300 -34.43%
on 01/22/26
+0.0300 (+2.56%)
since 01/09/26
3-Month
1.1000 +9.09%
on 01/30/26
1.8300 -34.43%
on 01/22/26
-0.0500 (-4.00%)
since 11/07/25
52-Week
0.2800 +328.57%
on 03/03/25
1.8300 -34.43%
on 01/22/26
+0.4865 (+68.19%)
since 02/07/25

Most Recent Stories

More News
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the closing of its previously announced underwritten public offering...

LXRX : 1.2000 (-2.44%)
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering...

LXRX : 1.2000 (-2.44%)
Lexicon Announces Proposed Public Offering of Common Stock

THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer...

LXRX : 1.2000 (-2.44%)
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January...

LXRX : 1.2000 (-2.44%)
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S....

LXRX : 1.2000 (-2.44%)
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista...

LXRX : 1.2000 (-2.44%)
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” 

-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers...

LXRX : 1.2000 (-2.44%)
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare...

LXRX : 1.2000 (-2.44%)
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as...

LXRX : 1.2000 (-2.44%)
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin...

LXRX : 1.2000 (-2.44%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 1.2983
2nd Resistance Point 1.2667
1st Resistance Point 1.2333
Last Price 1.2000
1st Support Level 1.1683
2nd Support Level 1.1367
3rd Support Level 1.1033

See More

52-Week High 1.8300
Fibonacci 61.8% 1.2379
Last Price 1.2000
Fibonacci 50% 1.0550
Fibonacci 38.2% 0.8721
52-Week Low 0.2800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar